LakeShore Biopharma Co., Ltd
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Wang Xu
- Full Time Employees
- 758
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Building No. 2 Beijing People's Republic of China 102629
- IPO Date
- Aug 5, 2021
- CIK
- 0001946399
- Website
- ysbiopharm.com
- Similar Companies
- Business
- LakeShore Biopharma Co., Ltd (NASDAQ: LSB) is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of innovative vaccines and therapeutic biologics targeting infectious diseases and cancer; its proprietary PIKA immunomodulating technology platform drives a pipeline including the marketed YSJA rabies vaccine, the first aluminum-free lyophilized rabies vaccine in China; PIKA rabies vaccine in Phase I/III trials; PIKA YS-HBV-001 and PIKA YS-HBV-002 for hepatitis B prevention and chronic infection treatment in Phase I and preclinical stages, respectively; PIKA YS-ON-001 immuno-oncology candidate in Phase I for pancreatic and hepatocellular cancers; and preclinical candidates for influenza, shingles, coronavirus, and other viral infections. Founded in 1994 and headquartered in Beijing, China, at Building No. 2, 38 Yongda Road, Daxing Biomedical Industry Park, the company operates primarily in China, Singapore, the Philippines, the United States, and the United Arab Emirates, serving markets for preventive vaccines and immunotherapeutics with approximately 573 employees. Formerly known as YS Biopharma Co., Ltd., it changed its name to LakeShore Biopharma in May 2024 to better align with its global positioning; recent developments include a US$15 million private placement financing in July 2025 with an institutional investor issuing ordinary shares and warrants; entry into a definitive agreement in November 2025 for a going-private transaction; receipt of preliminary non-binding acquisition proposals in August 2025, including a revised one from a consortium; Philippine FDA approval in April 2024 for Phase I trials of YS-HBV-002; and transition to OTC markets following Nasdaq delisting.
LSB Industries: Ongoing Margin Execution Is Not Being Appreciated Enough
LSB Industries Reaches Agreement Establishing a Pathway to 100% Ownership of El Dorado CCS Project
LSBCF Investors Have Opportunity to Join LakeShore Biopharma Co., Ltd Fraud Investigation with the Schall Law Firm
LSB Industries, Inc. Reports Operating Results for the 2026 First Quarter
LSB Industries, Inc. Schedules 2026 First Quarter Results Release for Wednesday, April 29th and Conference Call for Thursday, April 30th
LSB Industries, Inc. Appoints Jonathan Ackerman as an Independent Member of the Board of Directors; Announces Retirement of Steve Packebush
LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company
LSB Industries: Strong 2025 And Massive NOLs Lead To Poison Pill Defense
LSB Industries, Inc. Reports Operating Results for the 2025 Fourth Quarter and Full Year and Provides Product Sales Volume Outlook for 2026
LSB Industries, Inc. Schedules 2025 Fourth Quarter and Full Year Results Release for Wednesday, February 25th and Conference Call for Thursday, February 26th
LakeShore Biopharma Announces Receipt of Buyer Group Notice and Postponement of Extraordinary General Meeting of Shareholders
LakeShore Biopharma to Hold Extraordinary General Meeting of Shareholders
LSB Industries, Inc. to Participate in NYSE Industrials Virtual Conference
LakeShore Biopharma Enters into Definitive Agreement for Going-Private Transaction
LSB Industries, Inc. Reports Operating Results for the 2025 Third Quarter
LSB Industries, Inc. Schedules 2025 Third Quarter Results Release for Wednesday, October 29th and Conference Call for Thursday, October 30th
LakeShore Biopharma Announces Transition to OTC Market Following Nasdaq Delisting
LakeShore Biopharma Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee
LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee
LSB Industries, Inc. to Participate in Upcoming Investor Conferences